Resultats de la cerca - Graham Cooksley
- Mostrar 1 - 3 resultats de 3
-
1
HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B per Michael Fried, Teerha Piratvisuth, George Lau, Patrick Marcellin, Wan-Cheng Chow, Graham Cooksley, Kang-Xian Luo, Seung Woon Paik, Yun–Fan Liaw, Peter Button, M. Popescu
Publicat 2008Artigo -
2
The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C per Tarek Hassanein, Graham Cooksley, Mark Sulkowski, Coleman Smith, George Marinos, Ming‐Yang Lai, Giuseppe Pastore, R. Trejo-Estrada, Ana Horta e Vale, Neil Wintfeld, Jesse Green
Publicat 2004Artigo -
3
Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B per George Lau, Teerha Piratvisuth, Kang Luo, Patrick Marcellin, Satawat Thongsawat, Graham Cooksley, Edward Gane, Michael Fried, Wan Cheng Chow, Seung Woon Paik, Wen Yu Chang, Thomas Berg, Robert Flisiak, Philip McCloud, N. Pluck
Publicat 2005Artigo
Eines de cerca:
Matèries relacionades
Chronic hepatitis
Gastroenterology
Internal medicine
Medicine
Peginterferon alfa-2a
Ribavirin
Virus
Alpha interferon
Alternative medicine
HBeAg
HBsAg
Hepatitis B virus
Immunology
Interferon
Interferon alfa
Pathology
Placebo
Seroconversion
Virology
Adverse effect
Combination therapy
Hepatitis B
Hepatitis C
Lamivudine
Nursing
Pegylated interferon
Quality of life (healthcare)